Raymond James & Associates Amarin Corp Plcuk Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Amarin Corp Plcuk stock. As of the latest transaction made, Raymond James & Associates holds 34,559 shares of AMRN stock, worth $23,845. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,559
Previous 33,939
1.83%
Holding current value
$23,845
Previous $29,000
3.45%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding AMRN
# of Institutions
184Shares Held
87.9MCall Options Held
528KPut Options Held
219K-
Sarissa Capital Management LP Greenwich, CT24.9MShares$17.1 Million3.87% of portfolio
-
Kynam Capital Management, LP Princeton, NJ12MShares$8.3 Million1.12% of portfolio
-
Dg Capital Management, LLC New York, NY6.44MShares$4.45 Million3.54% of portfolio
-
Eversept Partners, LP New York, NY6.21MShares$4.29 Million0.42% of portfolio
-
Morgan Stanley New York, NY3.61MShares$2.49 Million0.0% of portfolio
About AMARIN CORP PLCUK
- Ticker AMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 403,206,016
- Market Cap $278M
- Description
- Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...